Similar Items: Cost utility and budget impact analysis of bortezomib and lenalidomide for the treatment of relapsed/refractory multiple myeloma in the South African public health sector
- A bibliometric analysis of the research landscape of lenalidomide resistance in multiple myeloma
- Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions
- Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Receiving Teclistamab: A Panel Chart Review Study
- Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases
- Potential of oncolytic viruses in the treatment of multiple myeloma
- Integrin alpha8beta1 is Identified as a Potential CAR-T Target for BCMA-Resistant Relapsed Multiple Myeloma
Author: Cleary, Susan
- Conducting a cost analysis to address issues of budget constraints on the implementation of the indoor residual spray program. an intervention to control and eliminate Malaria in two districts of Maputo Province, Mozambique
- Expanded programme for immunisation: Review of the Western Cape Department of health public private partnership
- Examining priority setting and resource allocation practices in county hospitals in Kenya
- Equity and efficiency in health and health care for HIV-positive adults in South Africa
- Structure and agency in the economics of public policy for TB control
- An analysis of expenditure on HIV/AIDS patients in Zambia